Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. TREM2 and immune genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

Homozygous mutations in exon 2 of TREM2, a gene involved in Nasu-Hakola disease, can cause frontotemporal dementia (FTD). Moreover, a rare TREM2 exon 2 variant (p.R47H) was reported to increase the risk of Alzheimer's disease (AD) with an odds ratio as strong as that for APOEε4. We systematically screened the TREM2 coding region within a Belgian study on neurodegenerative brain diseases (1216 AD patients, 357 FTD patients, and 1094 controls).

What this study adds

Evidence grade: High

This is a pooled review. In a Belgian sample, rare TREM2 variants were enriched in both Alzheimer's disease and frontotemporal dementia patients compared with controls, most notably in the extracellular IgV-set domain. This identifies genetic risk associations only and does not show any way to treat, cure or prevent Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cuyvers, E., Bettens, K., Philtjens, S., Van Langenhove, T., Gijselinck, I., van der Zee, J., et al. (2014). Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiology of aging. https://doi.org/10.1016/j.neurobiolaging.2013.09.009

Vancouver

Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiology of aging. 2014. doi:10.1016/j.neurobiolaging.2013.09.009. PMID: 24119542.

BibTeX

@article{cuyvers2014-24119542,
  author  = {Cuyvers, E. and Bettens, K. and Philtjens, S. and Van Langenhove, T. and Gijselinck, I. and van der Zee, J. and Engelborghs, S. and Vandenbulcke, M. and others},
  title   = {{Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia}},
  journal = {Neurobiology of aging},
  year    = {2014},
  doi     = {10.1016/j.neurobiolaging.2013.09.009},
  pmid    = {24119542},
  url     = {https://doi.org/10.1016/j.neurobiolaging.2013.09.009}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In a Belgian sample, rare TREM2 variants were enriched in both Alzheimer's disease and frontotemporal dementia patients compared with controls, most notably in the extracellular IgV-set domain. This identifies genetic risk associations only and does not show any way to treat, cure or prevent Alzheimer's disease.

Study details

How this study scored 64/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 4 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 64 of 100.64 of 100 points earned36 not earned

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurobiology of aging)
Journal's citation record 3 / 4 Neurobiology of Aging: journal h-index 263 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2014 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 5 / 7 Cited 183 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 13.1 citations a year over 14 year(s) since 2014
Impact for its field and year 4 / 6 Cited 12.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 61 other studies in this library
Still being cited 2 / 4 Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Kristel Sleegers: h-index 81 (OpenAlex, whole career)
Institution's track record 1 / 3 KU Leuven: institution h-index 1,386 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24119542)
Free to read 0 / 2 Behind a paywall — scores zero
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

61 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in TREM2 and immune genetics from nearby years

Also tagged “r47h”

363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on TREM2 and immune genetics

See all studies in TREM2 and immune genetics →